Indeed, the presence of PD-L1 does partially predict responses to anti-PD-(L)1 CPIs in several cancers including NSCLC, triple-negative breast, cervical, gastric/gastroesophageal and urothelial cancers [[97], [98], [99], [100], [101], [102]] and, in some cases, is used to guide anti-PD-(L)1 therapy [103]. This evidence concerns the gene CD274 and cancer.